<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="6483">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01823003</url>
  </required_header>
  <id_info>
    <org_study_id>sbrt_lung_fff2012</org_study_id>
    <nct_id>NCT01823003</nct_id>
  </id_info>
  <brief_title>Risk Adapted SABR(SABR) in Stage I NSCLC And Lung Metastases</brief_title>
  <acronym>sbrtlungfff</acronym>
  <official_title>Risk Adapted Free Flattering Filter Based Stereotactic Ablative Radiotherapy (Sabr) in Stage i Nsclc and Lung Metastases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Català d'Oncologia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut Català d'Oncologia</source>
  <oversight_info>
    <authority>Spain: Ethics Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to evaluate the safety of Stereotactic Ablative Radiotherapy (SBRT)
      in selected patients with stage I Non Small Cell Lung Cancer (NSCLC) or metastatic lung
      cancer to demonstrate the feasibility and risks of using an ablative dose-adapted scheme
      with FFF beams. Other aims are To evaluate the incidence of acute and late complications; To
      evaluate tumour response to local radiation therapy by means of CT, PET/TC and MRI and To
      evaluate the impact of local therapy on overall and disease-free survival.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The intervention (dose and fractions) depends on topographical parameters: lung disease
      (primary, peripheral nodes or mediastinal nodes), distance to chest wall, tumour size and
      distance to main bronchus.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2012</start_date>
  <completion_date type="Anticipated">June 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>probability of not suffering a grade 3 or higher toxicity</measure>
    <time_frame>one year</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Patients will be follow-up during one year. If patient suffered any toxicity grade 3 or higher during this period it will be classified as having toxicity. Otherwise patient will be classified as not having toxicity.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tumour response</measure>
    <time_frame>One year</time_frame>
    <safety_issue>No</safety_issue>
    <description>To evaluate tumour response attending histology with local radiation using imaging such as CT and PET/CT.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of acute and late toxicities</measure>
    <time_frame>One year</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>To evaluate the frequency of acute and late toxicities.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>One year</time_frame>
    <safety_issue>No</safety_issue>
    <description>To evaluate the impact of local therapy on overall survival.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-free survival</measure>
    <time_frame>One year</time_frame>
    <safety_issue>No</safety_issue>
    <description>To evaluate the impact of local therapy on disease-free survival.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect in brochopulmonary (COPD) disease.</measure>
    <time_frame>One year</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>To evaluate the impact of local therapy on bronchopulmonary (COPD) disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Feasibility</measure>
    <time_frame>One year</time_frame>
    <safety_issue>No</safety_issue>
    <description>To evaluate the feasibility of this technique in terms of technical complications.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">56</enrollment>
  <condition>Carcinoma, Non-Small-Cell Lung</condition>
  <condition>Neoplasm Metastasis</condition>
  <arm_group>
    <arm_group_label>A. 34 Gy in a single fraction</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>34 Gy by single fraction Risk-adapted radiation dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B. 54Gy (18Gy/fr. x 3 fractions)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>54Gy administered in 3 fraction of 18 Gy, risk adapted radiation dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C. 50Gy (12 x 5 fr.s)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>54Gy administered in 5 fraction of 12 Gy, risk adapted radiation dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>D. 60Gy (7.5Gy x 8fr.)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>60 Gy administered in 8 fraction of 7.5 Gy, risk adapted radiation dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>34 Gy in a single fraction</intervention_name>
    <description>34 Gy in a single fraction in case of Distance to chest wall &gt; 1 cm, tumour size &lt; 2 cm and distance to the main bronchus &gt; 2 cm. STEREOTACTIC ABLATIVE RADIOTHERAPY (SABR) will be administered with volumetric modulated arcs, with photon beam energy of 6-10 MV. The number of arcs and their ballistic is left undefined in order to allow for optimization of the dose distribution. Bolus is not allowed.</description>
    <arm_group_label>A. 34 Gy in a single fraction</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>54Gy 18Gy/fr. x 3 fractions</intervention_name>
    <description>54Gy administered in 3 fractions of 18Gy in case of distance to chest wall &gt; 1 cm, tumour size between 2 and 5 cm and distance to the main bronchus &gt; 2 cm. STEREOTACTIC ABLATIVE RADIOTHERAPY (SABR)will be administered with volumetric modulated arcs, with photon beam energy of 6-10 MV. The number of arcs and their ballistic is left undefined in order to allow for optimization of the dose distribution. Bolus is not allowed.</description>
    <arm_group_label>B. 54Gy (18Gy/fr. x 3 fractions)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>50Gy (12 x 5 fr.s)</intervention_name>
    <description>50Gy administered in 5 fractions of 12 Gy for Peripheral Nodes in case of distance to chest wall &lt; 1 cm, tumour size &lt; 5 cm and distance to main bronchus &gt; 2 cm. STEREOTACTIC ABLATIVE RADIOTHERAPY (SABR) will be administered with volumetric modulated arcs, with photon beam energy of 6-10 MV. The number of arcs and their ballistic is left undefined in order to allow for optimization of the dose distribution. Bolus is not allowed.</description>
    <arm_group_label>C. 50Gy (12 x 5 fr.s)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>60Gy (7.5Gy x 8fr.)</intervention_name>
    <description>60 Gy administered in 8 fractions of 7.5 Gy for mediastinal nodes in case of tumour size &lt; 5 cm and distance to the main bronchus &lt; 2 cm. STEREOTACTIC ABLATIVE RADIOTHERAPY (SABR)will be administered with volumetric modulated arcs, with photon beam energy of 6-10 MV. The number of arcs and their ballistic is left undefined in order to allow for optimization of the dose distribution. Bolus is not allowed.</description>
    <arm_group_label>D. 60Gy (7.5Gy x 8fr.)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically-confirmed primary lung cancer or lung metastasis from another primary
             tumour or positive PET/CT suggestive for primary tumour(SUV MAX&gt; 4).

          -  Tumour size &lt; 5 cm in diameter prior to treatment.

          -  Medically inoperable patients as determined by the multidisciplinary thoracic tumour
             board, or medically operable patients who refuse surgery.

          -  Life expectancy of &gt;12 months.

          -  Criterion for medical inoperability include:

        Overall clinical assessment at the UCLA thoracic tumour board. Reduced Pulmonary Function
        (FEV1, DLCO, etc) based on one major or two minor criterion as described below: Minor
        Criteria: Age &gt; 75, FEV1 51- 60% predicted, or FEV1 1-1.2L, DLCO 51%-60% predicted,
        pulmonary hypertension, poor left ventricular function (EF &lt; 40% or less), resting or
        exercise arterial pO2 &lt; 55 mmHg, and pCO2 &gt; 45 mmHg.

          -  Age &gt; 18 years.

          -  KPS &gt; 70.

          -  Barthel score &gt;40

          -  Baseline computed tomography scans of the chest, pulmonary test function, and
             positron emission tomography no more than 2 months before treatment.

          -  If a woman is of childbearing potential, a negative urine or serum pregnancy test
             must be documented.

          -  Ability to understand and the willingness to sign a written informed consent.

        Exclusion Criteria:

          -  Prior thoracic radiation treatment wich dose contribution can be expected in the new
             SBRT plan.

          -  More than two lesions per lobe.

          -  Active infections requiring systemic antibiotics.

          -  Age &lt;18 years old.

          -  KPs &lt; 70.

          -  Barthel Total Score &lt; 40.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arturo Navarro-Martin, md</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut Català d'Oncologia - L'Hospitalet</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Arturo Navarro-Martin, MD</last_name>
    <phone>+34.93.260.77.22</phone>
    <email>anavarro@iconcologia.net</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Valentín Navarro-Pérez</last_name>
    <phone>+34.93.260.78.22</phone>
    <email>vnavarro@iconcologia.net</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Institut Català d'Oncologia - L'Hospitalet</name>
      <address>
        <city>L'Hospitalet del Llobregat</city>
        <state>Barcelona</state>
        <zip>08908</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arturo Navarro-Martin, MD</last_name>
      <phone>+34.93.260.77.22</phone>
      <email>anavarro@iconcologia.net</email>
    </contact>
    <contact_backup>
      <last_name>Valentín Navarro-Pérez</last_name>
      <phone>+34.93.260.78.22</phone>
      <email>vnavarro@iconcologia.net</email>
    </contact_backup>
    <investigator>
      <last_name>Arturo Navarro-Martín, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>María Dolores Arnáiz-Fernández, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 10, 2014</lastchanged_date>
  <firstreceived_date>March 25, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Carcinoma, Non-Small-Cell Lung</keyword>
  <keyword>Neoplasm Metastasis</keyword>
  <keyword>Radiosurgery</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Neoplasms, Second Primary</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
